Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma

Journal of Investigative Dermatology

Volumn 128, Issue 8, 2008, Pages 2003-2012

  Houben, Roland ^a   Vetter Kauczok, Claudia S ^a   Ortmann, Sonja ^a   Rapp, Ulf R ^b   Broecker, Eva B ^a   Becker, Juergen C ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ARTICLE; B RAF KINASE GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; NRAS GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STAINING; TUMOR CELL;

EID: 47349103884     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.30     Document Type: Article

References (42)

1. Baccarini M (2005) Second nature: biological functions of the Raf-1 "kinase". FEBS Lett 579:3271-7
2. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A (2006) Molecularly targeted therapy for melanoma: current reality and future options. Cancer 107:2317-27
3. Caunt CJ, Finch AR, Sedgley KR, McArdle CA (2006) Seven-transmembrane receptor signalling and ERK compartmentalization. Trends Endocrinol Metab 17:276-83
4. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B et al. (2001) MAP kinases. Chem Rev 101:2449-76
5. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G et al. (2002) Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:3728-33
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
7. Dhillon AS, Kolch W (2002) Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys 404:3-9
8. Dhillon AS, Meikle S, Peyssonnaux C, Grindlay J, Kaiser C, Steen H et al. (2003) A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol 23:1983-93
9. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA et al. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66:9483-91
10. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95:581-6
11. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA (2006) Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25:3956-62
12. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z et al. (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878-89
13. Garnett MJ, Rana S, Paterson H, Barford D, Marais R (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20:963-9
14. Giehl K (2005) Oncogenic Ras in tumour progression and metastasis. Biol Chem 386:193-205
15. Hagan S, Al Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B et al. (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11:7392-7
16. Horgan AM, Stork PJ (2003) Examining the mechanism of Erk nuclear translocation using green fluorescent protein. Exp Cell Res 285:208-20
17. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R et al. (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3:6
18. Houben R, Michel B, Vetter-Kauczok CS, Pfohler C, Laetsch B, Wolter MD et al. (2006) Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol 126:1135-42
19. Houslay MD, Kolch W (2000) Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-68
20. Howe AK, Aplin AE, Juliano RL (2002) Anchorage-dependent ERK signaling - mechanisms and consequences. Curr Opin Genet Dev 12:30-5
21. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A (2004) Integrin regulation of cell signalling and motility. Biochem Soc Trans 32:443-6
22. Kondoh K, Torii S, Nishida E (2005) Control of MAP kinase signaling to the nucleus. Chromosoma 114:86-91
23. Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139
24. Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A et al. (2007) ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 127:2207-15
25. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y et al. (2007) Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98:652-8
26. Nilsson K, Landberg G (2006) Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer 118:1120-5
27. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169-200
28. Park S, Yeung ML, Beach S, Shields JM, Yeung KC (2005) RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535-40
29. Rapp UR, Gotz R, Albert S (2006) BuCy RAFs drive cells into MEK addiction. Cancer Cell 9:9-12
30. Sacks DB (2006) The role of scaffold proteins in MEK/ERK signalling. Biochem Soc Trans 34:833-6
31. Schlaepfer DD, Hauck CR, Sieg DJ (1999) Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71:435-78
32. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186-92
33. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB et al. (2003) PAK1 phosphorylation of MEK1 regulates fibronectin- stimulated MAPK activation. J Cell Biol 162:281-91
34. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-62
35. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19:19-25
36. Uribe P, Andrade L, Gonzalez S (2006) Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 126:161-6
37. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67
38. Wayne J, Sielski J, Rizvi A, Georges K, Hutter D (2006) ERK regulation upon contact inhibition in fibroblasts. Mol Cell Biochem 286:181-9
39. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C et al. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-7
40. Zebisch A, Troppmair J (2006) Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 63:1314-30
41. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD et al. (2005) Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58:1163-9
42. Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I et al. (2007) Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57:12-20